 VANCOUVER, British Columbia, May 04, 2021 GLOBE NEWSWIRE -- InMed Pharmaceuticals Inc. InMed or the Company Nasdaq: INM; TSX:IN, a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol CBN, today announced that Eric. A. Adams, President and CEO of InMed, will be presenting at Canaccord Genuitys 5th Annual Global Cannabis Conference on Tuesday, May 11th, which is being held virtually this year. Details on the conference and how to participate are below. 